Real news gives us facts about important issues

Let you know us better and enjoy our news and stories.

Contact us
Annual lookback
23 December 2020
20 was a big challenge for everyone. A challenge to adapt to a new situation has taught us to pay more attention to each other, to better appreciate everyone and everything around us. Thus, we also realized the importance of human relationships not only with colleagues but also with our clients. This year has taught us to look for solutions to situations we have not encountered so far. We have learned that online work also bears fruit, we have learned to treat each other with much more patience and adaptation in this way, we have learned to work with our children 😊 Despite all the changes, we feel that we coped well the obstacles and we had a successful year compared to the new situation. A brief business summary of the year of 2020: • Our support team performed outstandingly this year as well, despite the distance, we successfully completed all our support projects, as before. We will continue to strive to manage these projects with great care in the future too. Thanks to the support team for their work. • We have successfully submitted several EU projects, which we look forward to hearing from them and we appreciate a lot our team for their hard work. • Our skillful project team managed to launch several new projects: MAIB - Cash management, Uniprest Instal - Digital Advisory project, Streamerse - streaming platform, Alphablock - development project, we had several projects for our KPEye product, we also created several new platforms for our new clients We can say that we are closing the year with satisfaction, we are waiting for the next year with many novelties and new plans. We wish for all our colleagues, existing and new clients a happy holiday and a successful 2021.
Recent entries

The Network Science Institute - TRACKING COVID-19 IN THE AGE OF A.I.
25 September 2020
 As the COVID-19 pandemic intensifies, researchers are working to develop pharmaceutical drugs that slow the virus’s reach, heal the ill, and may offer a vaccine. But what if promising therapies already exist? Albert-László Barabási, Robert Gray Dodge Professor of Network Science, Distinguished Professor of Physics, and Director of the Center for Complex Network Research, has assembled a multidisciplinary team that is using network medicine to hunt for a COVID-19 treatment. LEADING THE FIGHT AGAINST COVID-19 With traditional lengthy drug development pipelines now impracticable, Barabási is exploring repurposing approved drugs with known toxicity and side effects that may have a therapeutic effect on COVID-19 patients. Armed with powerful data, he is scrutinizing how the virus invades healthy cells, pinpointing drugs to treat the virus, and validating those drugs using artificial intelligence/machine learning bioinformatics and trials.  In March, the Barabási Lab began re-curating its past work on the human interactome, an intracellular and intercellular network of protein interaction. Less than 10 days after starting, the team identified 40 medications that target the cellular areas where COVID-19 works. The virus latches on to a healthy cell’s proteins, then disrupts functions within that cell and generates millions more copies of itself. The lab developed a network model of the 332 proteins targeted by COVID-19, and examined how the virus’s perturbing activity might affect tissues and organs. For example, using this model to examine how COVID-19 binds with host proteins, the lab predicted that the virus could attack cells in the brain—which may explain why early symptoms in people with COVID-19 include loss of the senses of smell and taste. Now, after forecasting the cellular progression of COVID-19, Barabási is looking for drugs and experimental compounds that could fight the virus by targeting proteins in its network vicinity. With Harvard Medical School researchers, he is combing through data on drugs that could be repurposed to treat COVID-19. To advance this work, Barabási and his team are performing computation to better grasp how the virus hijacks healthy cells; using 3D modeling to understand and predict its spread; and conducting experimental validation to identify drugs that could ultimately help combat COVID-19. Source: